Neurocrine Biosciences Inc. (NBIX)

100.83
NASDAQ : Health Technology
Prev Close 101.50
Day Low/High 100.49 / 102.50
52 Wk Low/High 64.72 / 125.59
Avg Volume 658.40K
Exchange NASDAQ
Shares Outstanding 91.58M
Market Cap 9.30B
EPS 0.20
P/E Ratio 505.60
Div & Yield N.A. (N.A)
Commit To Purchase Neurocrine Biosciences At $11, Earn 23.9% Annualized Using Options

Commit To Purchase Neurocrine Biosciences At $11, Earn 23.9% Annualized Using Options

Investors eyeing a purchase of Neurocrine Biosciences, Inc. stock, but tentative about paying the going market price of $14.27/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Heavy Trading On Neurocrine Biosciences (NBIX) Before Market Open

Heavy Trading On Neurocrine Biosciences (NBIX) Before Market Open

Trade-Ideas LLC identified Neurocrine Biosciences (NBIX) as a pre-market mover with heavy volume candidate

Multiple Sectors Punch Market to New Highs

February's final week suggests a window-dressing event in response to the massive recovery in play since the low three weeks ago.

It's Hard to Believe, but Biotech Stocks Are Starting 2014 Hotter Than 2013

It's Hard to Believe, but Biotech Stocks Are Starting 2014 Hotter Than 2013

Biotech and drug stocks are up almost 9% to start 2014, trouncing the broader market averages.

Insider Trading Alert - NDSN, FNSR, NUVA, DECK And NBIX Traded By Insiders

Insider Trading Alert - NDSN, FNSR, NUVA, DECK And NBIX Traded By Insiders

Stocks with insider trader activity include NDSN, FNSR, NUVA, DECK and NBIX

Insider Trading Alert - NDSN, FNSR, NUVA, DECK And NBIX Traded By Insiders

Insider Trading Alert - NDSN, FNSR, NUVA, DECK And NBIX Traded By Insiders

Stocks with insider trader activity include NDSN, FNSR, NUVA, DECK and NBIX

Biotech Trading 2014 Starts Hot, But Surprise, Last Year Was Even Better

Biotech Trading 2014 Starts Hot, But Surprise, Last Year Was Even Better

The biotech sector has jumped off to a strong start to 2014, with today's blockbuster move in Intercept Pharma offering a big assist. I know it's ridiculously early to make any sort of definitive judgment, but I wondered how the first days of biotech trading 2014 compared to 2013. Here are the charts:

Insider Trading Alert - SWI, ADBE, GLUU, NBIX And AXE Traded By Insiders

Insider Trading Alert - SWI, ADBE, GLUU, NBIX And AXE Traded By Insiders

Stocks with insider trader activity include SWI, ADBE, GLUU, NBIX and AXE

Insider Trading Alert - SWI, ADBE, GLUU, NBIX And AXE Traded By Insiders

Insider Trading Alert - SWI, ADBE, GLUU, NBIX And AXE Traded By Insiders

Stocks with insider trader activity include SWI, ADBE, GLUU, NBIX and AXE

Trade-Ideas: Neurocrine Biosciences (NBIX) Is Today's "Perilous Reversal" Stock

Trade-Ideas: Neurocrine Biosciences (NBIX) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Neurocrine Biosciences (NBIX) as a "perilous reversal" (up big yesterday but down big today) candidate

Why Neurocrine Biosciences (NBIX) Is Spiking Today

Why Neurocrine Biosciences (NBIX) Is Spiking Today

Shares of Neurocrine Biosciences (NBIX) rose Tuesday based on a positive mid-stage study of an experimental drug.

Heavy Trading On Neurocrine Biosciences (NBIX) Before Market Open

Heavy Trading On Neurocrine Biosciences (NBIX) Before Market Open

Trade-Ideas LLC identified Neurocrine Biosciences (NBIX) as a pre-market mover with heavy volume candidate

First Week Of August 16th Options Trading For Neurocrine Biosciences (NBIX)

First Week Of August 16th Options Trading For Neurocrine Biosciences (NBIX)

Investors in Neurocrine Biosciences, Inc. saw new options become available this week, for the August 16th expiration.

December 2014 Options Now Available For Neurocrine Biosciences (NBIX)

December 2014 Options Now Available For Neurocrine Biosciences (NBIX)

Investors in Neurocrine Biosciences, Inc. saw new options become available today, for the December 2014 expiration.

Interesting NBIX Put And Call Options For December 21st

Interesting NBIX Put And Call Options For December 21st

Investors in Neurocrine Biosciences, Inc. saw new options begin trading this week, for the December 21st expiration.

January 2015 Options Now Available For Neurocrine Biosciences (NBIX)

January 2015 Options Now Available For Neurocrine Biosciences (NBIX)

Investors in Neurocrine Biosciences, Inc. saw new options begin trading today, for the January 2015 expiration.

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

These stocks look ready to break out and trade higher from current levels.

First Week Of NBIX May 2014 Options Trading

First Week Of NBIX May 2014 Options Trading

Investors in Neurocrine Biosciences, Inc. saw new options become available this week, for the May 2014 expiration.

Neurocrine Biosciences Becomes Oversold (NBIX)

Neurocrine Biosciences Becomes Oversold (NBIX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

4 Stocks Dragging In The Drugs Industry

4 Stocks Dragging In The Drugs Industry

TheStreet highlights 4 stocks pushing the drugs industry lower today.

5 Stocks Spiking on Unusual Volume

5 Stocks Spiking on Unusual Volume

Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

Interesting NBIX Put And Call For September 21st

Interesting NBIX Put And Call For September 21st

Investors in Neurocrine Biosciences, Inc. saw new options become available today, for the September 21st expiration.

'Mad Money' Lightning Round: Hold on to Sprint

'Mad Money' Lightning Round: Hold on to Sprint

Don't buy NQ Mobile but buy CVR Partners, Cramer said.

Cramer's 'Mad Money' Recap: Stop Being Complacent

Cramer's 'Mad Money' Recap: Stop Being Complacent

If you own a stock solely for its high dividend yield, it's time to start taking some profits, Cramer said.

Commit To Buy Neurocrine Biosciences At $9, Earn 28.8% Annualized

Commit To Buy Neurocrine Biosciences At $9, Earn 28.8% Annualized

Investors considering a purchase of Neurocrine Biosciences, Inc. stock, but cautious about paying the going market price of $12.91/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Ratings Changes Coming on 5/7/2013

Upgrades: BKCC, CENX, FRM, TLD, LPS, PMC, MCRI, SMRT, SYNM Downgrades: ALSK, BAP, BCO, DRRX, NBIX, OFIX, SMA, TLM Initiations: OSH

Neurocrine Biosciences Inc. Stock Downgraded (NBIX)

Neurocrine Biosciences Inc. Stock Downgraded (NBIX)

Neurocrine Biosciences (Nasdaq:NBIX) has been downgraded by TheStreet Ratings from from a buy to hold.

Another Biotech Play

Another Biotech Play

Keep this one on the radar for a pullback buying opportunity.

Neurocrine Biosciences Inc. Stock Upgraded (NBIX)

Neurocrine Biosciences Inc. Stock Upgraded (NBIX)

Neurocrine Biosciences (Nasdaq:NBIX) has been upgraded by TheStreet Ratings from a sell to buy.

Neurocrine Biosciences Inc. Stock Downgraded (NBIX)

Neurocrine Biosciences Inc. Stock Downgraded (NBIX)

Neurocrine Biosciences (Nasdaq:NBIX) has been downgraded by TheStreet Ratings from from a hold to sell.

TheStreet Quant Rating: C+ (Hold)